ArriVent Publishes FURTHER Phase 1b Results Of Firmonertinib In Cancer Cell
Share
Why It Matters
ArriVent shared new test results for a cancer medicine in early trials. Watch how doctors and patients respond to see if the drug works well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.